AA-LansoprazoleAmoxicillinClarithromycin · DIN 02470780 · 30 mg & 500 mg & 500 mg · tablet/capsule Pk
Limited Use, Reason for Use code 306, 307 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 306, 307 required
Write on scriptone applicable Reason for Use code, 306 or 307 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 306, 307
Reason for Use code 306
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, breath test or endoscopy, for a course of up to 14 days.
Maximum duration: 14 days.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 307
For the retreatment of H. pylori-positive peptic ulcers where H. pylori recurrence or persistence is documented, by breath test or endoscopy, for a course of up to 14 days.
Maximum duration: 14 days (after a four-week period has elapsed since the end of the previous treatment)
Coverage limit:
Retreatment decisions should be based upon positive symptoms and positive endoscopy or positive urea breath test. Retreatment should not be based on a positive serology test, as serology tests may remain positive indefinitely. An alternative antibiotic regimen is recommended when initial therapy fails due to concerns of antimicrobial resistance.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
AA-LansoprazoleAmoxicillinClarithromycin · DIN 02470780
Manufacturer: A A Pharma Inc.; listing date 2018-09-27
Health Canada: Marketed since 2022-10-04 · brand AA-LANSOPRAZOLE-AMOXICILLIN-CLARITHROMYCIN · ATC A02BD07 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN · form Kit, Capsule (delayed-release), Capsule, Tablet · route Oral · ingredients LANSOPRAZOLE 30 MG/CAP, AMOXICILLIN 500 MG/CAP, CLARITHROMYCIN 500 MG/TAB · company Aa pharma inc · schedule Prescription
AA-LansoprazoleAmoxicillinClarithromycin: Formulary list price $67.91 per unit (the source does not state the unit; exact figure $67.9100). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02470780)
Source record
DIN 02470780: AA-LansoprazoleAmoxicillinClarithromycin
Raw flags: sec12=Y, sec3=Y
Item: 564000091; group id 681; item number 1698; lccId 00104; manufacturer id AAP
Source form: Tab/Cap Pk; strength: 30mg & 500mg & 500mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $67.9100; ministry $67.9100
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02470780
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95983
Interchangeable products
Hp-PAC · DIN 02238525 · not recorded
Shortage status: not checked (no credentials)